23rd April 2019

Consilium Strategic Communications is supporting ARM’s inaugural 2019 Cell & Gene Meeting on the Mediterranean 

~Consilium is ARM’s retained strategic communications advisor in Europe and official media partner for the meeting~

 

London, 23 April 2019, Consilium Strategic Communications, a global leader in strategic healthcare communications and investor relations, is pleased to be supporting the Alliance of Regenerative Medicine (ARM) as its official Media Partner at the inaugural Cell & Gene Meeting on the Mediterranean, taking place from 23-25 April in Barcelona, Spain.

ARM is an international multi-stakeholder advocacy organization that promotes legislative, regulatory, and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. The event, modelled on ARM’s highly successful Cell & Gene Meeting on the Mesa, brings together the entire cell and gene therapy community from Europe and beyond. The program, which is expected to attract more than 250 attendees, will feature expert-led panels, extensive one-on-one partnering capabilities, exclusive networking opportunities, and 50+ dedicated presentations by the leading publicly traded and privately held companies in the space.  Panels and discussions will focus on some of the key topics and issues facing the sector, including manufacturing, pricing and reimbursement, and the scientific, clinical, and regulatory landscape going forward.

“We are pleased to be ARM’s retained strategic communications advisor in Europe and official media partner at the inaugural Meeting on the Mediterranean in Barcelona. ARM has produced a fantastic program with many high quality, expert speakers. We are looking forward to the meeting and to welcoming the industry, regulators, investors and media, that are attending.”

Chris Gardner

Partner of Consilium Strategic Communications

“We are excited to be hosting our very first 2019 Cell & Gene Meeting on the Mediterranean starting today in Barcelona and are very grateful for the support Consilium has provided. Europe plays a significant role across all areas of cell and gene therapies and this is a fantastic opportunity to bring leading experts, companies, industry bodies and regulators together to discuss these potentially transformative therapies and how we can work together to make them available to patients.”

Janet Lambert

CEO of ARM

For members of the media interested in speaking to attendees, please contact Matthew Neal / Sarah Wilson on ARM@consilium-comms.com

Confirmed speakers include:

  • Guido Rasi, Director General, European Medicines Agency (EMA)
  • Keith Thompson, CEO, Cell and Gene Therapy Catapult
  • Matthew Durdy, Chief Business Officer, Cell and Gene Therapy Catapult
  • Dan Faga, Chief Business Officer, Spark Therapeutics
  • Alison Finger, Chief Commercial Officer, bluebird bio
  • Claire Foreman, Head of Acute Programs, National Health Service
  • Owen Marks, Country Lead, Rare Diseases, Pfizer
  • Pascal Touchon, SVP, Global Head of Cell and Gene Europe, Novartis
  • Luca Alberici, Ph.D., Chief Business Officer, MolMed
  • Etienne Jousseaume, Head of Market Access, Cell and Gene Europe, Novartis
  • Jason Meyenburg, Chief Commercial Officer, Orchard Therapeutics
  • Usman Azam, President and CEO, Tmunity Therapeutics
  • Thomas Fellner, Ph.D., Head of Cell and Gene Therapy, Lonza
  • Joseph Tarnowski, Ph.D., SVP, Cell and Gene Therapy Platforms, Medicinal Science and Technology, R&D, GSK
  • Matthew Patterson, Chairman and CEO, Audentes Therapeutics; Chairman, Alliance for Regenerative Medicine
  • Amy DuRoss, Co-Founder and CEO, Vineti
  • Sven Kili, M.D., Principal, Sven Kili Consulting
  • Christopher Vann, Chief Operating Officer, Autolus Therapeutics
  • Rogerio Vivaldi, M.D., President and CEO, Sigilon Therapeutics
  • Ian Hudson, M.D., Chief Executive, Medicines and Healthcare Products Regulatory Agency
  • Katsuaki Ura, Deputy Director, Office of International Regulatory Affairs, Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare

 

2019 presenting companies include: 3Scan; Adaptimmune; AGTC; Akron Biotech; Andalusian Initiative for Advanced Therapies; Aspect Biosystems; Audentes Therapeutics; Avectas; Axovant Gene Therapies; Biostage; bluebird bio; BlueRock Therapeutics; B-MoGen Biotechnologies; Bone Therapeutics; Caribou Biosciences; CEVEC Pharmaceuticals; Chimeric Therapeutics; Cryoport; Cynata Therapeutics; DiscGenics; FloDesign Sonics; FUJIFILM Cellular Dynamics; Genethon; Giner Life Sciences; Healios; Invitrx Therapeutics; Iovance Biotherapeutics; Kiadis Pharma; LogicBio Therapeutics; MaxCyte; MolMed; NAVAN Technologies; Novadip Biosciences; Orchard Therapeutics; Organovo; ORIG3N; Oxford Biomedica; panCELLa; PDC*line Pharma; PolarityTE; Promethera Biosciences; REGENXBIO; ReNeuron; Rexgenero; Sangamo Therapeutics; Sigilon Therapeutics; Spark Therapeutics; Terumo BCT; TikoMed; T-knife; Tmunity Therapeutics; uniQure; VERIGRAFT; Vivet Therapeutics; and Zelluna Immunotherapy.

For full details on the agenda, access to the live webcast or further information about the event, please visit www.meetingonthemed.com

 

-Ends-

 

For more information, please contact:

 

Consilium Strategic Communications

Mary-Jane Elliott / Amber Fennell

Tel: +44(0)20 3709 5700

info@consilium-comms.com

www.consilium-comms.com

Follow us: @consiliumhc

 

Consilium Strategic Communications US

Catherine London, US President

Tel: +1 917-763-2709

E-mail: London@consilium-comms.com

 

About Consilium Strategic Communications

Consilium Strategic Communications is a global leader in financial and corporate communications and investor relations focused on the healthcare sector. Consilium's team, based in both Europe and US, provides strategic, long-term PR and IR advice to healthcare companies, Boards, senior decision makers and executives on critical communications programmes, international media management, transactions and healthcare stakeholder challenges. Consilium has established deep knowledge and expertise across all areas of the global healthcare sector through broad involvement in representing international clients spanning the Fortune 500, FTSE 100, FTSEurofirst 300 and FTSE 250, through to discrete specialist reputation management projects. For more information please see www.consilium-comms.com

 

About the Alliance for Regenerative Medicine 

The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory, and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. Founded in 2009, ARM works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its 330+ member organizations worldwide. ARM represents the interests of therapeutic developers, academic research institutions, major medical centres, investors, and patient groups that comprise the broader regenerative medicine community and is the prominent international advocacy organization in this field.

 

ARM has 70+ members across 15 countries in Europe. ARM aims to work closely with European stakeholders, leveraging its membership to create a supportive commercial and regulatory environment to create better conditions for the development and commercialization of ATMPs in Europe; develop strong stakeholder support around proposed solutions to improve patient access to ATMPs; promote clear, predictable and efficient regulatory framework across Europe; and promote international convergence of key regulations and guidances.


Back to previous page